Syed Muhammad ObaidUllah April 3, 2017 Kevetrin Cellceutix AACR Poster Presents Data Supporting Kevetrin Modulation of p53 in Multiple Human Ovarian Cancer Cell-lines and Corresponding Xenograft Tumors
Syed Muhammad ObaidUllah March 27, 2017 Brilacidin Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis (OM) in Head and Neck Cancer Patients; High Potential for Preventative Treatment
Philip Drake March 21, 2017 Brilacidin Cellceutix Releases Favorable Topline Findings as Part of Interim Analysis of Phase 2 Drug Candidate Brilacidin for the Treatment of Inflammatory Bowel Disease
Philip Drake March 16, 2017 Brilacidin Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease
Philip Drake March 8, 2017 Brilacidin Cellceutix Releases Preliminary Efficacy and Safety Data in Interim Analysis of First Two Cohorts in Phase 2 Trial of Brilacidin for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
Philip Drake March 3, 2017 Kevetrin Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent
Philip Drake February 22, 2017 Brilacidin Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
Philip Drake February 16, 2017 Corporate Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical Milestones
Philip Drake February 10, 2017 Kevetrin Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p53 Drug Candidate Kevetrin in the Treatment of Platinum-Resistant/Refractory Ovarian Cancer
Philip Drake January 23, 2017 Brilacidin Cellceutix’s Brilacidin Demonstrates Promise in Treating Ulcerative Colitis Supported by Endoscopic Assessment, Patient-Reported Outcomes
Philip Drake January 17, 2017 Corporate Cellceutix Strongly Denounces Criminal Enterprise Mako Research, Who Published “Fake News” Full of Lies and Innuendo
Philip Drake January 17, 2017 Brilacidin Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of Brilacidin for Inflammatory Bowel Disease
Philip Drake January 4, 2017 Corporate, Brilacidin Cellceutix to Present at Biotech Showcase 2017; Brilacidin for Oral Mucositis Nears Interim Results
Philip Drake December 22, 2016 Corporate Cellceutix Wishes Shareholders Happy Holidays, Prepares for 2017 Focused on Partnerships
Philip Drake December 19, 2016 Prurisol Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis Initiated and Open for Screening
Philip Drake December 15, 2016 Kevetrin Cellceutix Reports Advances in Developing Kevetrin as an Oral Ovarian Cancer Treatment; Company Seeks to Develop World’s First p53-Modulating Oral Cancer Drug
Philip Drake December 7, 2016 Brilacidin Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis
Philip Drake November 14, 2016 Corporate Cellceutix Provides Corporate Update and Reports Q1 Fiscal 2017 Financial Results
Philip Drake November 9, 2016 Corporate Cellceutix Announces Business Update Call at 10AM Eastern on November 15
Philip Drake October 31, 2016 Prurisol Cellceutix Begins Phase 2b Clinical Trial of Oral Prurisol in Moderate-to-Severe Chronic Plaque Psoriasis
